Febrile Neutropenia Test Of Cure Visit Timing Should Be Reassessed - Cmte.
Executive Summary
FDA should consider shortening the time to test-of-cure visit in trials of empiric antibiotic therapies for febrile neutropenia, FDA's Anti-Infective Drugs Advisory Committee recommended July 31.